Turnium Appoints Industry Veteran as VP of Global Strategy and Partnerships to Accelerate International Growth

Vancouver, British Columbia–(Newsfile Corp. – January 5, 2026) – Turnium Technology Group Inc. (TSXV: TTGI) (FSE: E48) (“Turnium” or the “Company“), a global leader in Technology-as-a-Service (TaaS) and partner enablement services, is pleased to announce the appointment of Aldo G. Gallone as Vice President of Global Strategy and Partnerships. Mr. Gallone brings over 35 years […]

Collagen Water Market Size to Worth USD 11.46 Billion by 2035 | Towards FnB

Collagen Water Market Size to Worth USD 11.46 Billion by 2035 | Towards FnB According to Towards FnB, the global collagen water market size is evaluated at USD 5.76 billion in 2026 and expand to approximately USD 11.46 billion by 2035, registering at a CAGR of 7.94% from 2026 to 2035. This growth trajectory highlights

Parashift positioned as a Leader in the SPARK Matrix(TM): Intelligent Document Processing (IDP), 2025 by QKS Group

Pune, India, Jan. 05, 2026 (GLOBE NEWSWIRE) — The QKS Group SPARK Matrix(TM) provides competitive analysis & ranking of the leading IDP vendors. Parashift, powered by its proprietary Document Swarm Learning(R) and a cloud-native, compliance-first architecture has received strong ratings across technology excellence and customer impact. QKS Group announced today that it has named Parashift

ORCL ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Oracle Corporation Shareholders Who Lost Money

NEW YORK, NY / ACCESS Newswire / January 5, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oracle Corporation ("Oracle Corporation") (NYSE:ORCL) concerning possible violations of federal securities laws. What Happened? • On the evening of December 10, 2025, Oracle issued its second quarter earnings report for fiscal year

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

(NasdaqGM:ALT), GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment of patients with

Validic Powers Scalable AI-Driven Remote Care at CES 2026

LAS VEGAS, Jan. 05, 2026 (GLOBE NEWSWIRE) — Validic, the connected health data platform, today announced its participation at CES 2026, where it will highlight how its AI-enabled platform transforms continuous device and wearable data into clinically relevant insights delivered across EHR and care coordination systems. Validic's platform uses generative AI to synthesize high-volume health

SAGA Metals Reports Strongest Critical Mineral Drill Results To-Date at Radar Ti-V-Fe Project in Labrador

(TSX-V:SAGA),(Boerse Frankfurt – Freiverkehr:20H),(OTC US:SAGMF),(Other OTC:SAGMF), –First Assay Results Reported for the Trapper Zone Following Completion of the 2025 Phase of the Mineral Resource Estimate Drill Program– VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) — SAGA Metals Corp. (“SAGA” or the “Company”) (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company focused

3D Systems Accelerates Growth in Aerospace & Defense with Strategic Investments and Projected Leadership Position

(NYSE:DDD), ROCK HILL, S.C., Jan. 05, 2026 (GLOBE NEWSWIRE) — 3D Systems (NYSE: DDD), a leading provider of additive manufacturing solutions, today announced significant momentum in its Aerospace & Defense (A&D) business, including robust revenue growth projections, a major U.S. facility expansion, and key technological advancements. These initiatives position the company to capitalize on rising

Copperhead Resources Announces Changes in Officers

(CNSX:CUH), Vancouver, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) — Copperhead Resources Inc. (CSE: CUH) (“Copperhead” or the “Company”) announces that Kevin Zhou has resigned as an officer of the Company. The Company thanks Mr. Zhou for his contributions and service. The Company is also pleased to announce that Denise Lok, Chief Financial Officer and

Angitia Biopharmaceuticals Completes Enrollment of Phase 2 ARTEMIS Trial Evaluating AGA2118 for the Treatment of Osteoporosis

– Company expects topline data from the study in 2027 WESTLAKE VILLAGE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) — Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the completion of enrollment in the Phase 2 ARTEMIS trial evaluating AGA2118, a bispecific antibody

Scroll to Top